Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chuankezhi (CKZ) is an injectable traditional Chinese medicine (TCM) approved in China for the treatment of bronchial asthma. [3] It is composed of extracts from two herbs: Epimedium (Yin Yang Huo) and Morinda officinalis (Ba Ji Tian). [4] In TCM theory, it is used to warm the kidney-yang, relieve coughs and asthma, and has anti-allergic and immune-enhancing functions. [2, 8] Chuankezhi is administered via intramuscular injection. [4, 8] Clinical research and network pharmacology studies suggest its therapeutic effects may be due to the regulation of immune function and anti-inflammatory pathways. [4, 9, 10] For example, studies indicate it may activate the PI3K-Akt signaling pathway and modulate the IL-17 signaling pathway. [4, 10] It is being investigated for other conditions, including atopic dermatitis, chronic obstructive pulmonary disease (COPD), and steroid-resistant focal segmental glomerulosclerosis (FSGS). [4, 5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chuankezhi.